Navigation Links
Part I. Not for release, publication or distribution, in whole or in part, directly or indirectly, in, into or from any jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.
Date:7/18/2014

i) either (a) the requisite AbbVie Stockholder approval is not obtained at the relevant AbbVie Stockholder Meeting or (b) that meeting has not been held within 60 days after the adverse change or modification of the recommendation or (c) the Co-operation Agreement terminates as a result of the Scheme or Offer being withdrawn or lapsing following such AbbVie Board change or modification of recommendation; or
  • on or before the final Long Stop Date, the Scheme or Offer is withdrawn as a result of AbbVie invoking and being permitted by the Panel to invoke any regulatory condition, being any condition in paragraphs 3(d) to 3(j) inclusive of Appendix I, or AbbVie not waiving a regulatory condition which is not met, or if the European Commission on or before such date initiates a Phase 2 review under the EU Merger Regulation or a similar event has occurred in the EU.
  • AbbVie has agreed to make a cost reimbursement payment to reimburse and compensate Shire for its costs, losses and expenses in connection with the Transaction, in the event that the Transaction fails to close following a negative AbbVie Stockholder vote; such cost reimbursement payment shall equal not less than $500 million, but shall be capped at one per cent. of the transaction value referred to, calculated on the basis described above in this sub-paragraph.

    Only one break fee or cost reimbursement payment shall be made and it shall be Shire's exclusive remedy in the relevant circumstance.

    The Co-operation Agreement contains provisions in relation to the Shire Share Schemes. Details of these arrangements will be set out in the Scheme Circular.

    19.
    Overseas shareholdersThe availability of the New AbbVie Shares under the terms of the Merger to persons not resident in the United Kingdom or Jersey may be affected by the laws and regulations of the relevant jurisdiction. Such persons should inform themselves about and observe any applicable requirements. Further detai
    '/>"/>

    SOURCE AbbVie Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

    Related medicine technology :

    1. North American Drug Delivery Technologies Market (Metered Dose Inhalers, Needle-Free Injectors, Auto-Injectors, Nasal Sprays, Transdermal Patches, Nebulizers, Infusion Pumps, Drug Eluting Stents, Sustained Release, Ocular Implants) - Forecasts To 20
    2. aTyr Pharma Announces Publication of a Rare Muscle Disease Associated with Regulation of a Potential Physiocrine
    3. BioLineRx Reports Publication in Peer Review Journal of Positive Phase 1/2 Results in Stem Cell Mobilization for Multiple Myeloma
    4. Micell Technologies Announces DESSOLVE I Manuscript Accepted for Publication in American College of Cardiologys Cardiovascular Interventions Journal
    5. Avanir Pharmaceuticals Announces Publication of AVP-825 Pharmacokinetic Data in Journal "Headache"
    6. Avanir Pharmaceuticals Announces Publication of PRISM Pseudobulbar Affect Registry Findings
    7. BioLineRx Announces Publication of Positive Pre-Clinical Results for BL-8040 in Treatment of Thrombocytopenia
    8. Sangamo BioSciences Announces Publication of First Demonstration of Inactivation of Extra Chromosome Responsible for Down Syndrome
    9. SI-BONE, Inc. Announces Publication of Postmarket Surveillance Safety Data on First 5,319 Patients Treated with iFuse Implant System
    10. Metabolic Solutions Development Company announces publication of data describing potential for new drugs to maintain pancreatic beta-cells in treating diabetes
    11. Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/6/2015)... July 6, 2015 Array BioPharma,s (NASDAQ: ... this past weekend at the 2015 ESMO World ... At the meeting, data were shared from a ... 100-patient randomized Phase 2 expansion of that trial ... EGFR inhibitor, with or without the addition of ...
    (Date:7/6/2015)... 6, 2015 Akcea Therapeutics, a wholly-owned ... ), announced today that the U.S. Food and ... volanesorsen (ISIS-APOCIII Rx ) for the treatment of ... a rare genetic disease characterized by extremely high ... Phase 2 study published in the NEJM in ...
    (Date:7/4/2015)... BARCELONA , España, July 4, 2015 /PRNewswire/ ... SIR-Spheres® Y-90 a la quimioterapia de primera línea ... en el hígado (mCRC) extiende la supervivencia libre ... pacientes con cáncer colorrectal metastásico no resecable (mCRC) ... la mayor mejora en la supervivencia libre de ...
    Breaking Medicine Technology:Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 2Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 3Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 4Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 2Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 3Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 4Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 5Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 6El Congreso Mundial del Cáncer Gastrointestinal presenta nuevos datos del estudio SIRFLOX 2El Congreso Mundial del Cáncer Gastrointestinal presenta nuevos datos del estudio SIRFLOX 3El Congreso Mundial del Cáncer Gastrointestinal presenta nuevos datos del estudio SIRFLOX 4El Congreso Mundial del Cáncer Gastrointestinal presenta nuevos datos del estudio SIRFLOX 5
    ... February 27 Novagali Pharma, a French,pharmaceutical ... first set of,data pertaining to Nova21027, its ... Novagali communicated about "Ocular ... conventional formulations of prostaglandin,analogues: an in vivo ...
    ... /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: ... of its new drug application ("NDA") for AFRESA(R), an ultra ... As previously announced, our internal goal was to submit the ... end of February. Based on editorial decisions made during ...
    Cached Medicine Technology:Novagali Pharma Presents Results of its Innovative Latanoprost Formulation for Glaucoma 2MannKind Updates Status of NDA Submission for AFRESA 2MannKind Updates Status of NDA Submission for AFRESA 3
    (Date:7/7/2015)... ... July 07, 2015 , ... ... communication management solutions, has announced the release of Service Pack 5600 for ... includes a number of enhancements to the already robust capabilities of the ...
    (Date:7/7/2015)... ... July 07, 2015 , ... CareSync proudly announces ... recognized by the White House as a “Champion of Change” for Precision Medicine ... Initiative, the Champions of Change program recognizes Gleason and eight other extraordinary individuals ...
    (Date:7/6/2015)... ... July 06, 2015 , ... ... stages of drug discovery. iPSCs are generated from adult cells, such as blood ... cell type in the human body. , iPSC-derived cardiomyocytes have ...
    (Date:7/6/2015)... ... July 06, 2015 , ... In order to ... American Orthopaedic Society for Sports Medicine ( AOSSM ) will present ten research ... As a leader in orthopaedic sports medicine, AOSSM annually provides more than ...
    (Date:7/6/2015)... ... July 06, 2015 , ... ... year for aesthetic reasons, which is why liposuction regularly ranks among the top ... however, fat reduction has become more than a way to slim down a ...
    Breaking Medicine News(10 mins):Health News:ISI Telemanagement Solutions, Inc. Releases Service Pack 5600 for Infortel® Select 2Health News:White House names Champions of Change for Precision Medicine: CareSync COO Recognized 2Health News:White House names Champions of Change for Precision Medicine: CareSync COO Recognized 3Health News:Cellular Dynamics’ Webinar Underscores the Value of Using Human iPSC-derived Cardiomyocytes for Investigative in vitro Drug Toxicology 2Health News:Cellular Dynamics’ Webinar Underscores the Value of Using Human iPSC-derived Cardiomyocytes for Investigative in vitro Drug Toxicology 3Health News:Cellular Dynamics’ Webinar Underscores the Value of Using Human iPSC-derived Cardiomyocytes for Investigative in vitro Drug Toxicology 4Health News:American Orthopaedic Society for Sports Medicine (AOSSM) Presents Prestigious Research Awards at Annual Meeting 2Health News:American Orthopaedic Society for Sports Medicine (AOSSM) Presents Prestigious Research Awards at Annual Meeting 3Health News:American Orthopaedic Society for Sports Medicine (AOSSM) Presents Prestigious Research Awards at Annual Meeting 4Health News:American Orthopaedic Society for Sports Medicine (AOSSM) Presents Prestigious Research Awards at Annual Meeting 5Health News:American Orthopaedic Society for Sports Medicine (AOSSM) Presents Prestigious Research Awards at Annual Meeting 6Health News:Learn How CoolSculpting® and Liposuction in Virginia Beach Help Military Members Stay the Course 2Health News:Learn How CoolSculpting® and Liposuction in Virginia Beach Help Military Members Stay the Course 3
    ... AGA Medical Corporation ("AGA,Medical") announced today that it ... and Welfare (MHLW) for its AMPLATZER(R) Duct Occluder ... used for the,non-surgical closure of patent ductus arteriosus ... occurs when a blood vessel known as the ...
    ... Medical Innovations, Inc. (NYSE: IMA ), a ... solutions, has introduced the pima(TM) analyzer, a ... The initial application of the instrument will be a ... instrument is one of several novel technologies under development ...
    ... national health care reform a top priority of the ... proposals swirling about Washington, D.C., and around the country, ... stepping up its efforts to identify and launch new ... care delivery systems.With health care reform a central feature ...
    ... awareness and knowledge of Daiichi Sankyo,s innovative treatmentsPARSIPPANY, N.J., ... it has established a subsidiary -- Daiichi Sankyo de ... Inc. is based in San Juan, and led by ... more than 20 years of experience in pharmaceutical sales ...
    ... FDA-approved once-daily amoxicillin will be promoted to health ... Pharmaceuticals, Inc. (Nasdaq: MBRK ), today ... extended-release) Tablets, 775mg, will begin on March 16, ... of its 270-person field force which will promote ...
    ... - Hard to Treat Diseases (HTDS) www.htdsmedical.com ... identified a cosmetics company as a potential merger candidate. ... is engaged in online sales of the "Melem" product. ... It has a wide variety of skin and lip ...
    Cached Medicine News:Health News:AGA Medical Receives Japanese Approval for AMPLATZER(R) Duct Occluder 2Health News:AGA Medical Receives Japanese Approval for AMPLATZER(R) Duct Occluder 3Health News:Inverness Medical Innovations Presents the pima(TM) Point-of-Care CD4 Instrument at ICASA 2008 2Health News:Inverness Medical Innovations Presents the pima(TM) Point-of-Care CD4 Instrument at ICASA 2008 3Health News:Newly Reactivated Health Economics Research Institute to Launch New Initiatives for Improving Health Care Delivery 2Health News:Newly Reactivated Health Economics Research Institute to Launch New Initiatives for Improving Health Care Delivery 3Health News:Daiichi Sankyo, Inc. Establishes Subsidiary in Puerto Rico 2Health News:MiddleBrook Pharmaceuticals to Launch Moxatag(TM) March 2009 2Health News:MiddleBrook Pharmaceuticals to Launch Moxatag(TM) March 2009 3Health News:MiddleBrook Pharmaceuticals to Launch Moxatag(TM) March 2009 4Health News:Hard To Treat Diseases (HTDS) Set To Acquire Cosmetics Company 2
    ... determination of Ang II is ... the pharmacological effect and efficiency ... angiotensin converting enzyme inhibitors (ACE ... antagonists as well as for ...
    ... antigen test is a visual ... presumptive qualitative detection of Respitory ... specimens in neonatal and pediatric ... test has a built-in procedural ...
    Rapid Immunoassay for the detection of Respiratory Syncytial Virus....
    ... BD Directigen EZ RSV Test utilizes a new, ... one device for rapid RSV detection. The testing ... method whereby dried reagents have already been applied ... a two-step process, with clear-cut results shown by ...
    Medicine Products: